FDA clears UCLA heart tissue regeneration drug AD-NP1 for clinical trials. Funded entirely by taxpayer dollars, this first-of-its-kind drug targets cellular metabolism to promote tissue repair of multiple organs October 7, 2025 read more on the UCLA Newsroom page